Discloses herein are conjugates of a protein and one or more reducing sugars, wherein one, two, three or more target amino groups of the protein are glycated. Also disclosed are methods for the preparation of the glycated protein. Conjugates having one or more ketoamine linkages are efficiently prepared through the reaction between the protein and reducing sugars and exhibit desirable pharmaceutical properties.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
C07K 1/107 - Procédés généraux de préparation de peptides par modification chimique de peptides précurseurs
C07K 1/113 - Procédés généraux de préparation de peptides par modification chimique de peptides précurseurs sans changement de la structure primaire
C07K 2/00 - Peptides à nombre indéterminé d'amino-acidesLeurs dérivés
C07K 9/00 - Peptides ayant jusqu'à 20 amino-acides, contenant des radicaux saccharide et comportant une séquence entièrement déterminéeLeurs dérivés
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
The invention provides a an inactive, non-replicating vaccine comprising whole virion, chemically inactivated Yellow Fever virus which is inactivated using a method that ensures preservation of critical, neutralizing epitopes. The Yellow Fever virus has been adapted to propagate in cells to higher yields than the unadapted virus. The invention also provides methods for preventing Yellow Fever viral infection.
The invention provides a an inactive, non-replicating vaccine comprising whole virion, chemically inactivated Yellow Fever virus which is inactivated using a method that ensures preservation of critical, neutralizing epitopes. The Yellow Fever virus has been adapted to propagate in cells to higher yields than the unadapted virus. The invention also provides methods for preventing Yellow Fever viral infection.
The invention provides a an inactive, non-replicating vaccine comprising whole virion,.chemically inactivated Yellow Fever virus which is inactivated using a method that ensures preservation of critical, neutralizing epitopes. The Yellow Fever virus has been adapted to propagate in cells to higher yields than the unadapted virus. The invention also provides methods for preventing Yellow Fever viral infection.
The invention provides a an inactive, non-replicating vaccine comprising whole virion,.chemically inactivated Yellow Fever virus which is inactivated using a method that ensures preservation of critical, neutralizing epitopes. The Yellow Fever virus has been adapted to propagate in cells to higher yields than the unadapted virus. The invention also provides methods for preventing Yellow Fever viral infection.
The invention provides a an inactive, non-replicating vaccine comprising whole virion,.chemically inactivated Yellow Fever virus which is inactivated using a method that ensures preservation of critical, neutralizing epitopes. The Yellow Fever virus has been adapted to propagate in cells to higher yields than the unadapted virus. The invention also provides methods for preventing Yellow Fever viral infection.
The invention provides a an inactive, non-replicating vaccine comprising whole virion,.chemically inactivated Yellow Fever virus which is inactivated using a method that ensures preservation of critical, neutralizing epitopes. The Yellow Fever virus has been adapted to propagate in cells to higher yields than the unadapted virus. The invention also provides methods for preventing Yellow Fever viral infection.
The invention provides a an inactive, non-replicating vaccine comprising whole virion,.chemically inactivated Yellow Fever virus which is inactivated using a method that ensures preservation of critical, neutralizing epitopes. The Yellow Fever virus has been adapted to propagate in cells to higher yields than the unadapted virus. The invention also provides methods for preventing Yellow Fever viral infection.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
35 - Publicité; Affaires commerciales
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
(1) Vaccines for the prevention of or antibodies for the treatment of diseases in humans caused by haemophilus influenzae, clostridium tetani, corynebacterium diphtheriae, rabies virus, streptococcus pneumoniae, streptococcus mutans, or streptococcus sobrinus. (1) Development of processes for the production or testing of vaccines and biopharmaceuticals for human use, or for the preparation of documentation for the production, testing, sales or governmental registration of vaccines or biopharmaceuticals for human use.
